• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Christopher Simon to the Board of Directors

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $HAE alert in real time by email

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.

    For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company, a strategy and management consulting firm, where he led the Global Medical Products Practice. Prior to his career at McKinsey & Company, Mr. Simon served in commercial and operating roles at Baxter Healthcare Corporation, now Baxter International Inc., a healthcare company, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. He brings more than 30 years of experience in helping businesses transform and grow.



    "We are excited to welcome Chris to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Chris's leadership experience as a public company CEO and his extensive commercial and strategic experience in the life sciences industry will serve as tremendous assets as we continue to grow."

    Mr. Simon also currently serves on the board of directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts 
    Jason Peterson

    Vice President Investor Relations & Treasurer, Sotera Health

    IR@soterahealth.com
     
      
      
    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    kgibbs@soterahealth.com
     

    Source: Sotera Health Company



    Primary Logo

    Get the next $HAE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE
    $SHC

    CompanyDatePrice TargetRatingAnalyst
    Haemonetics Corporation
    $HAE
    5/22/2026$80.00Neutral → Buy
    BofA Securities
    Haemonetics Corporation
    $HAE
    5/12/2026$94.00 → $89.00Outperform
    Barrington Research
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    Sotera Health Company
    $SHC
    12/18/2025Outperform
    William Blair
    Haemonetics Corporation
    $HAE
    12/15/2025Buy → Hold
    Needham
    Haemonetics Corporation
    $HAE
    12/11/2025$88.00Buy → Neutral
    Citigroup
    Sotera Health Company
    $SHC
    11/13/2025$19.00Outperform
    BMO Capital Markets
    More analyst ratings

    $HAE
    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

    BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.ABOUT HAEMONETICSHaemonetics is a global medical technology co

    6/2/26 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registra

    5/11/26 4:33:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event

    5/7/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics upgraded by BofA Securities with a new price target

    BofA Securities upgraded Haemonetics from Neutral to Buy and set a new price target of $80.00

    5/22/26 8:18:54 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $89.00 from $94.00 previously

    5/12/26 8:01:51 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kroll Mark W bought $98,784 worth of shares (1,400 units at $70.56), increasing direct ownership by 6% to 24,757 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    11/12/25 4:18:34 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    SEC Filings

    View All

    SEC Form SD filed by Sotera Health Company

    SD - Sotera Health Co (0001822479) (Filer)

    5/29/26 4:05:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SD filed by Haemonetics Corporation

    SD - HAEMONETICS CORP (0000313143) (Filer)

    5/28/26 4:15:02 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sotera Health Co (0001822479) (Filer)

    5/22/26 4:09:28 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klee Ann R. was granted 14,970 shares, increasing direct ownership by 12% to 140,926 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 8:27:22 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Chief Executive Officer Shader Alton was granted 579,573 shares (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:54:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 3 filed by new insider Shader Alton

    3 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:47:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $HAE
    $SHC
    Financials

    Live finance-specific insights

    View All

    Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

    Financial release and supplemental presentation accessible onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event

    5/7/26 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces First-Quarter 2026 Earnings Release Date

    CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's operating and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's website at Presentation & Event

    4/21/26 7:46:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care